Correspondence 0001213900-24-100914 from NeuroSense Therapeutics Ltd. (NRSN, NRSNW) (CIK 0001875091) (NRSN)
NeuroSense Therapeutics Ltd. (NRSN, NRSNW) (CIK 0001875091)
Date: Nov. 21, 2024 · CIK: 0001875091 · Accession: 0001213900-24-100914
AI Filing Summary & Sentiment
File numbers found in text: 333-283338
Letter
NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
November 21, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE: NeuroSense Therapeutics Ltd. (CIK 0001875091)
Registration Statement No. 333-283338 on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
NeuroSense Therapeutics Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on November 22, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, P.A., by calling Gary Emmanuel at +972 (0) 3-636-6033. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.
Very truly yours,
NEUROSENSE THERAPEUTICS LTD.
Show Raw Text
CORRESP
1
filename1.htm
NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
November 21, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
NeuroSense Therapeutics Ltd. (CIK 0001875091)
Registration Statement No. 333-283338 on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
NeuroSense Therapeutics Ltd.
(the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement
pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective
on November 22, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The undersigned respectfully
requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, P.A.,
by calling Gary Emmanuel at +972 (0) 3-636-6033. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request
for acceleration.
Very truly yours,
NEUROSENSE THERAPEUTICS LTD.
By:
/s/ Alon Ben-Noon
Alon Ben-Noon
Chief Executive Officer